R&D Allocationv1 · 10.19
Looking across diseases for drugs that treat fibrosis ↗
Can comparing skin and lung fibrosis provide evidence for deciding which diseases to pursue with a drug?
3D-MOFIB plans to begin with scleroderma and pulmonary fibrosis associated with Hermansky–Pudlak syndrome, screening compounds and molecular activity in patient-derived models to explore shared fibrosis mechanisms and organ-specific differences.
- Research plan describedRecorded
- Test shared and distinct responsesUnverified
- Inform indication selectionUnverified
New question opened
Record a research plan to use shared fibrotic processes and organ differences in indication selection.
NEXT CHECK
Candidates with shared responses across skin and lung models, conditions that separate responses, reproducibility across donor samples and subsequent development decisions.
Evidence: NIH / NCATS ↗